🇺🇸 Pneumovax II in United States
100 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 100
Most-reported reactions
- Hypogammaglobulinaemia — 12 reports (12%)
- Immunodeficiency — 12 reports (12%)
- Tremor — 11 reports (11%)
- Feeling Of Body Temperature Change — 10 reports (10%)
- Food Interaction — 10 reports (10%)
- Hyperhidrosis — 10 reports (10%)
- Mental Disorder — 10 reports (10%)
- Tearfulness — 10 reports (10%)
- Foetal Distress Syndrome — 8 reports (8%)
- Drug Interaction — 7 reports (7%)
Other Immunology approved in United States
Frequently asked questions
Is Pneumovax II approved in United States?
Pneumovax II does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Pneumovax II in United States?
University of Oxford is the originator. The local marketing authorisation holder may differ — check the official source linked above.